QQQ   352.58 (+1.08%)
AAPL   179.97 (+1.21%)
MSFT   324.84 (+0.45%)
META   265.16 (+0.59%)
GOOGL   122.06 (-0.36%)
AMZN   123.82 (+2.14%)
TSLA   232.92 (+3.72%)
NVDA   386.70 (+3.19%)
NIO   7.69 (-0.90%)
BABA   86.44 (+1.36%)
AMD   120.91 (+2.61%)
T   16.02 (-0.50%)
F   13.61 (+0.15%)
MU   65.04 (-3.01%)
CGC   0.70 (-2.81%)
GE   106.79 (+0.67%)
DIS   92.36 (-0.17%)
AMC   4.66 (-1.48%)
PFE   39.06 (+0.44%)
PYPL   64.24 (+0.31%)
NFLX   405.44 (+1.42%)
QQQ   352.58 (+1.08%)
AAPL   179.97 (+1.21%)
MSFT   324.84 (+0.45%)
META   265.16 (+0.59%)
GOOGL   122.06 (-0.36%)
AMZN   123.82 (+2.14%)
TSLA   232.92 (+3.72%)
NVDA   386.70 (+3.19%)
NIO   7.69 (-0.90%)
BABA   86.44 (+1.36%)
AMD   120.91 (+2.61%)
T   16.02 (-0.50%)
F   13.61 (+0.15%)
MU   65.04 (-3.01%)
CGC   0.70 (-2.81%)
GE   106.79 (+0.67%)
DIS   92.36 (-0.17%)
AMC   4.66 (-1.48%)
PFE   39.06 (+0.44%)
PYPL   64.24 (+0.31%)
NFLX   405.44 (+1.42%)
QQQ   352.58 (+1.08%)
AAPL   179.97 (+1.21%)
MSFT   324.84 (+0.45%)
META   265.16 (+0.59%)
GOOGL   122.06 (-0.36%)
AMZN   123.82 (+2.14%)
TSLA   232.92 (+3.72%)
NVDA   386.70 (+3.19%)
NIO   7.69 (-0.90%)
BABA   86.44 (+1.36%)
AMD   120.91 (+2.61%)
T   16.02 (-0.50%)
F   13.61 (+0.15%)
MU   65.04 (-3.01%)
CGC   0.70 (-2.81%)
GE   106.79 (+0.67%)
DIS   92.36 (-0.17%)
AMC   4.66 (-1.48%)
PFE   39.06 (+0.44%)
PYPL   64.24 (+0.31%)
NFLX   405.44 (+1.42%)
QQQ   352.58 (+1.08%)
AAPL   179.97 (+1.21%)
MSFT   324.84 (+0.45%)
META   265.16 (+0.59%)
GOOGL   122.06 (-0.36%)
AMZN   123.82 (+2.14%)
TSLA   232.92 (+3.72%)
NVDA   386.70 (+3.19%)
NIO   7.69 (-0.90%)
BABA   86.44 (+1.36%)
AMD   120.91 (+2.61%)
T   16.02 (-0.50%)
F   13.61 (+0.15%)
MU   65.04 (-3.01%)
CGC   0.70 (-2.81%)
GE   106.79 (+0.67%)
DIS   92.36 (-0.17%)
AMC   4.66 (-1.48%)
PFE   39.06 (+0.44%)
PYPL   64.24 (+0.31%)
NFLX   405.44 (+1.42%)
Top-Rated StocksTop-Rated
NASDAQ:DICE

DICE Therapeutics (DICE) Stock Forecast, Price & News

$32.75
+0.22 (+0.68%)
(As of 02:34 PM ET)
Compare
Today's Range
$31.48
▼
$32.75
50-Day Range
$25.86
▼
$38.24
52-Week Range
$12.64
▼
$45.99
Volume
139,517 shs
Average Volume
456,366 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

DICE Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
91.1% Upside
$62.60 Price Target
Short Interest
Bearish
20.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of DICE Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$10.24 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.57) to ($3.57) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

481st out of 981 stocks

Pharmaceutical Preparations Industry

230th out of 481 stocks

See Top Rated MarketRank™ Stocks Here

DICE stock logo

About DICE Therapeutics (NASDAQ:DICE) Stock

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Stock News Headlines

June 5, 2023 | americanbankingnews.com
DICE Therapeutics, Inc. (NASDAQ:DICE) Insider Sells $572,437.50 in Stock
May 26, 2023 | americanbankingnews.com
DICE Therapeutics (NASDAQ:DICE) Now Covered by Wells Fargo & Company
June 8, 2023 | Edge On The Street (Ad)
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
May 25, 2023 | msn.com
Wells Fargo Initiates Coverage of DICE Therapeutics (DICE) with Equal-Weight Recommendation
May 24, 2023 | msn.com
DICE Therapeutics equalweight at Wells Fargo on lack of catalysts
May 24, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Hold Rating for Sana Biotechnology (SANA)
May 24, 2023 | americanbankingnews.com
DICE Therapeutics (NASDAQ:DICE) Shares Gap Up to $32.66
May 23, 2023 | proactiveinvestors.com
DICE Therapeutics psoriasis treatment has blockbuster potential, analysts say
June 8, 2023 | Edge On The Street (Ad)
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
May 23, 2023 | americanbankingnews.com
DICE Therapeutics (NASDAQ:DICE) Receives New Coverage from Analysts at Canaccord Genuity Group
May 23, 2023 | msn.com
Canaccord Genuity Initiates Coverage of DICE Therapeutics (DICE) with Buy Recommendation
May 22, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Gracell Biotechnologies (GRCL)
May 19, 2023 | americanbankingnews.com
Equities Analysts Issue Forecasts for DICE Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:DICE)
May 18, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for MiNK Therapeutics (INKT)
May 18, 2023 | americanbankingnews.com
Analysts Set DICE Therapeutics, Inc. (NASDAQ:DICE) Price Target at $64.63
May 15, 2023 | markets.businessinsider.com
Trevi Therapeutics (TRVI) Receives a Rating Update from a Top Analyst
May 15, 2023 | markets.businessinsider.com
Dice Therapeutics (DICE) Receives a Rating Update from a Top Analyst
May 12, 2023 | msn.com
HC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Buy Recommendation
May 12, 2023 | finanznachrichten.de
DICE Therapeutics, Inc.: DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 12, 2023 | markets.businessinsider.com
H.C. Wainwright Remains a Buy on Dice Therapeutics (DICE)
May 12, 2023 | americanbankingnews.com
DICE Therapeutics, Inc. (NASDAQ:DICE) Director Sells $3,238,575.47 in Stock
May 11, 2023 | msn.com
Recap: DICE Therapeutics Q1 Earnings
May 11, 2023 | seekingalpha.com
DICE Therapeutics GAAP EPS of -$0.54
May 11, 2023 | finance.yahoo.com
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 10, 2023 | benzinga.com
DICE Therapeutics Board Member Trades Company's Stock
May 8, 2023 | msn.com
DICE Therapeutics: Worth A Roll At The Right Price
May 8, 2023 | americanbankingnews.com
Insider Selling: DICE Therapeutics, Inc. (NASDAQ:DICE) CMO Sells $365,400.00 in Stock
See More Headlines

DICE Price History

DICE Company Calendar

Last Earnings
3/15/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DICE
CUSIP
N/A
CIK
1645569
Web
www.dicemolecules.com
Phone
650-566-1420
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.60
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+91.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-83,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-22.01%
Return on Assets
-20.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
32.44
Quick Ratio
32.44

Sales & Book Value

Annual Sales
$1.13 million
Price / Sales
1,383.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.89 per share
Price / Book
2.75

Miscellaneous

Outstanding Shares
47,730,000
Free Float
45,392,000
Market Cap
$1.56 billion
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Dr. J. Kevin Judice Ph.D. (Age 59)
    Founder, CEO & Director
    Comp: $840k
  • Mr. Scott Robertson
    Chief Bus. & Financial Officer
  • Dr. Timothy Lu M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700k
  • Dr. John R. Jacobsen Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Mary Riley J.D.
    Gen. Counsel
  • Mr. Venkat Thalladi Ph.D.
    Sr. VP of CMC
  • Mr. Paul Fatheree
    Sr. VP of Medicinal Chemistry

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DICE Stock - Frequently Asked Questions

Should I buy or sell DICE Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DICE shares.
View DICE analyst ratings or view top-rated stocks.

What is DICE Therapeutics' stock price forecast for 2023?

11 brokerages have issued 1 year target prices for DICE Therapeutics' shares. Their DICE share price forecasts range from $38.00 to $77.00. On average, they predict the company's share price to reach $62.60 in the next year. This suggests a possible upside of 91.1% from the stock's current price.
View analysts price targets for DICE or view top-rated stocks among Wall Street analysts.

How have DICE shares performed in 2023?

DICE Therapeutics' stock was trading at $31.20 at the start of the year. Since then, DICE stock has increased by 5.0% and is now trading at $32.75.
View the best growth stocks for 2023 here.

Are investors shorting DICE Therapeutics?

DICE Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 8,010,000 shares, a decline of 9.0% from the April 30th total of 8,800,000 shares. Based on an average daily volume of 526,900 shares, the days-to-cover ratio is currently 15.2 days. Approximately 20.8% of the shares of the stock are short sold.
View DICE Therapeutics' Short Interest.

When is DICE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our DICE earnings forecast.

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics, Inc. (NASDAQ:DICE) released its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.

What ETFs hold DICE Therapeutics' stock?

ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Pharmaceuticals ETF (IHE), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

When did DICE Therapeutics IPO?

(DICE) raised $160 million in an initial public offering on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share.

What is DICE Therapeutics' stock symbol?

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

Who are DICE Therapeutics' major shareholders?

DICE Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (11.90%), Avoro Capital Advisors LLC (8.28%), Price T Rowe Associates Inc. MD (6.82%), BlackRock Inc. (6.31%), Armistice Capital LLC (2.88%) and Baker BROS. Advisors LP (2.17%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson.
View institutional ownership trends.

How do I buy shares of DICE Therapeutics?

Shares of DICE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DICE Therapeutics' stock price today?

One share of DICE stock can currently be purchased for approximately $32.75.

How much money does DICE Therapeutics make?

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $1.56 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

How can I contact DICE Therapeutics?

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.

This page (NASDAQ:DICE) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -